ReviewExpert opinion on emerging drugs2018
PARP inhibitors for homologous recombination-deficient prostate cancer.
Eric S Christenson et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
17 papers cite it
this paperpooled itcites it